Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study

Adjuvant platinum-based chemotherapy is standard treatment for surgically resected stage II to IIIA NSCLC, but the relapse rate is high. The preferentially expressed antigen of melanoma (PRAME) tumor antigen is expressed in two-thirds of NSCLC and offers an attractive target for antigen-specific imm...

Celý popis

Podrobná bibliografie

Vydáno v:	Journal of thoracic oncology Ročník 11; číslo 12; s. 2208 - 2217
Hlavní autoři:	Pujol, Jean-Louis, De Pas, Tommaso, Rittmeyer, Achim, Vallières, Eric, Kubisa, Bartosz, Levchenko, Eugeny, Wiesemann, Sebastian, Masters, Gregory A, Shen, Robert, Tjulandin, Sergei A, Hofmann, Hans-Stefan, Vanhoutte, Nicolas, Salaun, Bruno, Debois, Muriel, Jarnjak, Silvija, De Sousa Alves, Pedro Miguel, Louahed, Jamila, Brichard, Vincent G, Lehmann, Frédéric F
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.12.2016
Témata:	Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Chemotherapy, Adjuvant - methods Female Humans Immunotherapy - methods Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Adjuvant setting PRAME antigen Safety NSCLC Immunotherapy
ISSN:	1556-1380
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!